Wilhelmina C M Duivenvoorden1, Siamak Daneshmand2, Daniel Canter3, Yair Lotan4, Peter C Black5, Hamidreza Abdi5, Bas W G van Rhijn6, Elisabeth E Fransen van de Putte6, Piotr Zareba1, Ilmari Koskinen7, Wassim Kassouf8, Samer L Traboulsi8, Janet E Kukreja9, Peter J Boström10, Bobby Shayegan1, Jehonathan H Pinthus11. 1. McMaster University and Juravinski Hospital, Hamilton, Ontario, Canada. 2. University of Southern California-Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California. 3. Fox Chase Cancer Center, Einstein Health Network and Urologic Institute of Southeastern Pennsylvania, Philadelphia, Pennsylvania. 4. University of Texas Southwestern Medical Center, Dallas, Texas. 5. Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada. 6. Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 7. Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 8. McGill University, Montreal, Quebec, Canada. 9. University of Rochester, Rochester, New York. 10. Turku University Hospital and University of Turku, Turku, Finland. 11. McMaster University and Juravinski Hospital, Hamilton, Ontario, Canada. Electronic address: pinthusj@hhsc.ca.
Abstract
PURPOSE: Neoadjuvant chemotherapy and pelvic surgery are significant risk factors for thromboembolic events. Our study objectives were to investigate the timing, incidence and characteristics of thromboembolic events during and after neoadjuvant chemotherapy and subsequent radical cystectomy in patients with muscle invasive bladder cancer. MATERIALS AND METHODS: We performed a multi-institutional retrospective analysis of 761 patients who underwent neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer from 2002 to 2014. Median followup from diagnosis was 21.4 months (range 3 to 272). Patient characteristics included the Khorana score, and the incidence and timing of thromboembolic events (before vs after radical cystectomy). Survival was calculated using the Kaplan-Meier method. The log rank test and multivariable Cox proportional hazards regression were used to compare survival between patients with vs without thromboembolic events. RESULTS: The Khorana score indicated an intermediate thromboembolic event risk in 88% of patients. The overall incidence of thromboembolic events in patients undergoing neoadjuvant chemotherapy was 14% with a wide variation of 5% to 32% among institutions. Patients with thromboembolic events were older (67.6 vs 64.6 years, p = 0.02) and received a longer neoadjuvant chemotherapy course (10.9 vs 9.7 weeks, p = 0.01) compared to patients without a thromboembolic event. Of the thromboembolic events 58% developed preoperatively and 72% were symptomatic. On multivariable regression analysis the development of a thromboembolic event was not significantly associated with decreased overall survival. However, pathological stage and a high Khorana score were adverse risk factors for overall survival. CONCLUSIONS: Thromboembolic events are common in patients with muscle invasive bladder cancer who undergo neoadjuvant chemotherapy before and after radical cystectomy. Our results suggest that a prospective trial of thromboembolic event prophylaxis during neoadjuvant chemotherapy is warranted.
PURPOSE: Neoadjuvant chemotherapy and pelvic surgery are significant risk factors for thromboembolic events. Our study objectives were to investigate the timing, incidence and characteristics of thromboembolic events during and after neoadjuvant chemotherapy and subsequent radical cystectomy in patients with muscle invasive bladder cancer. MATERIALS AND METHODS: We performed a multi-institutional retrospective analysis of 761 patients who underwent neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer from 2002 to 2014. Median followup from diagnosis was 21.4 months (range 3 to 272). Patient characteristics included the Khorana score, and the incidence and timing of thromboembolic events (before vs after radical cystectomy). Survival was calculated using the Kaplan-Meier method. The log rank test and multivariable Cox proportional hazards regression were used to compare survival between patients with vs without thromboembolic events. RESULTS: The Khorana score indicated an intermediate thromboembolic event risk in 88% of patients. The overall incidence of thromboembolic events in patients undergoing neoadjuvant chemotherapy was 14% with a wide variation of 5% to 32% among institutions. Patients with thromboembolic events were older (67.6 vs 64.6 years, p = 0.02) and received a longer neoadjuvant chemotherapy course (10.9 vs 9.7 weeks, p = 0.01) compared to patients without a thromboembolic event. Of the thromboembolic events 58% developed preoperatively and 72% were symptomatic. On multivariable regression analysis the development of a thromboembolic event was not significantly associated with decreased overall survival. However, pathological stage and a high Khorana score were adverse risk factors for overall survival. CONCLUSIONS:Thromboembolic events are common in patients with muscle invasive bladder cancer who undergo neoadjuvant chemotherapy before and after radical cystectomy. Our results suggest that a prospective trial of thromboembolic event prophylaxis during neoadjuvant chemotherapy is warranted.
Authors: Cliodhna Browne; Niall F Davis; William J Nolan; Eoin D MacCraith; Gerald M Lennon; David W Mulvin; David J Galvin; David M Quinlan Journal: Curr Urol Date: 2017-07-30
Authors: Andrew Amenyogbe; Francis Lemire; David Yachnin; Marc Carrier; Kristen McAlpine; Rodney H Breau; Dominick Bossé; Tzu-Fei Wang; Christopher Morash; Ilias Cagiannos; Luke T Lavallée Journal: Can Urol Assoc J Date: 2022-10 Impact factor: 2.052
Authors: Aditya Bagrodia; Ranjit Sukhu; Andrew G Winer; Eric Levy; Michael Vacchio; Byron Lee; Eugene J Pietzak; Timothy F Donahue; Eugene Cha; Gopa Iyer; Daniel D Sjoberg; Andrew J Vickers; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Bernard H Bochner Journal: Clin Genitourin Cancer Date: 2017-08-10 Impact factor: 2.872
Authors: Gopa Iyer; Christopher M Tully; Emily C Zabor; Bernard H Bochner; Guido Dalbagni; Harry W Herr; S Machelle Donat; Paul Russo; Irina Ostrovnaya; Ashley M Regazzi; Matthew I Milowsky; Jonathan E Rosenberg; Dean F Bajorin Journal: Clin Genitourin Cancer Date: 2020-03-06 Impact factor: 3.121
Authors: Tarik Benidir; Jaime Herrera-Caceres; Christopher Wallis; Katherine Lajkosz; Neil Fleshner Journal: Cancer Med Date: 2021-03-12 Impact factor: 4.452